Trends in Current Clinical Research on Herbal Medicines and Gut Microbiota
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Gut microbiota, regarded as the second genome of the human body, has become a key modulator of cancer treatment. It is an emerging topic in precision medicine, and many studies have reported that the variability in most diseases and individuals is related to gut microbiota characteristics. Numerous clinical studies on cancer treatment have demonstrated a correlation between therapeutic responses to immunotherapeutic cancer drugs and gut immunity or the microbiome. In this paper, we present the current clinical research on herbal medicines and gut microbiota and explore the possibility of integrative cancer treatment with herbal medicines and immunotherapeutic cancer drugs. We identified six clinical trials enrolled in the Clinical Research Information Service and five clinical studies on gut microbiota and herbal medicines in MEDLINE via PubMed. Generally, clinical studies have used 16S rRNA sequencing to analyze the gut microbiota. Study findings have suggested that the gut microbiota can be used as a biomarker to predict the pharmacological effects of herbal medicines. Gut microbiota modifications by herbal medicines may inhibit tumor progression. Herbal medicines are metabolized to active substances through interactions with the microbiome and control the dysbiosis of the gut microbiome. Further research on the possibility of individualized precision medicine by analyzing the gut microbiota after administering herbal medicine is needed.
Abstract
Gut microbiota, regarded as the second genome of the human body, has become a key modulator of cancer treatment. It is an emerging topic in precision medicine, and many studies have reported that the variability in most diseases and individuals is related to gut microbiota characteristics. Numerous clinical studies on cancer treatment have demonstrated a correlation between therapeutic responses to immunotherapeutic cancer drugs and gut immunity or the microbiome. In this paper, we present the current clinical research on herbal medicines and gut microbiota and explore the possibility of integrative cancer treatment with herbal medicines and immunotherapeutic cancer drugs. We identified six clinical trials enrolled in the Clinical Research Information Service and five clinical studies on gut microbiota and herbal medicines in MEDLINE via PubMed. Generally, clinical studies have used 16S rRNA sequencing to analyze the gut microbiota. Study findings have suggested that the gut microbiota can be used as a biomarker to predict the pharmacological effects of herbal medicines. Gut microbiota modifications by herbal medicines may inhibit tumor progression. Herbal medicines are metabolized to active substances through interactions with the microbiome and control the dysbiosis of the gut microbiome. Further research on the possibility of individualized precision medicine by analyzing the gut microbiota after administering herbal medicine is needed.
참고문헌 (27)
- E. Z. Gomaa, "Human gut microbiota", microbiome in health and diseases : a review, 2020, pp.113(12), 2019~2040
- T. M. Kuntz, "Introducing the Microbiome into Precision Medicine", Trends in Pharmacological Sciences, 38(1), pp.81~91 (2016)[DOI]
- V. Gopalakrishnan, "Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients", Science, 359(6371), pp.97~103 (2018)[DOI]
- E. N. Baruch, "Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients", Science, 371(6529), pp.602~609 (2021)[DOI]
- S. Gori, "Gut microbiota and cancer : How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy", Critical Reviews in Oncology, 2019, pp.143, 139~147
- K. Kang, "A comparative study on traditional constitutional medicine in the world", Korean Journal of Oriental Medicine, 15(3), pp.35~43 (2009)
- S. Song, "A study on the trend of world traditional medicine and key area of traditional Korean medicine(TKM)R&D", Korean Journal of Oriental Medicine, 16(1), pp.101~109 (2010)
- J. M. Han, "A Review on Korean Medicine and Personalized Medicine : Syndrome-based Personalized Medicine on the Basis of Syndrome Differentiation and Treatment", J Korean Med, 35(3), pp.40~48 (2014)[DOI]
- D. Ryu, "Current Trends and Future Directions of Gut Microbiota and Their-Derived Metabolite Study in the Pediatric Perspective of Korean Medicine", The Journal of Pediatrics of Korean Medicine, 33(1), pp.34~45 (2019)[DOI]
- X. An, "The interaction between the gut Microbiota and herbal medicines", Biomedicine & Pharmacotherapy, 118, pp.109252~ (2019)[DOI]
- H. R. Ahn, "A Review of the Experimental Studies on the Modulatory Effect Herbal Medicine on Gut Microbiota", The Journal of Pediatrics of Korean Medicine, 34(4), pp.43~58 (2020)[DOI]
- J. H. Park, "The role of gut microbiota in obesity and utilization of fermented herbal extracts", Journal of Society of Korean Medicine for Obesity Research, 9(1), pp.1~14 (2009)
- K. Ried, "Herbal formula improves upper and lower gastrointestinal symptoms and gut health in Australian adults with digestive disorders", Nutrition Research, 76, pp.37~51 (2020)[DOI]
- H. Yamashita, "Predicting Inchinkoto efficacy, in patients with obstructive jaundice associated with malignant tumors, through pharmacomicrobiomics", Pharmacological Research, 175, pp.105981~ (2022)[DOI]
- K. Hanada, "Effect of herbal medicine daikenchuto on gastrointestinal symptoms following laparoscopic colectomy in patients with colon cancer: A prospective randomized study", Biomedicine & Pharmacotherapy, 141, pp.111887~ (2021)[DOI]
- J. Zhang, "JianpiQinghua granule reduced PPI dosage in patients with nonerosive reflux disease: A multicenter, randomized, double-blind, double-dummy, noninferiority study", Phytomedicine, 88, pp.153584~ (2021)[DOI]
- S. Shao, "Xiao-Chai-Hu-Tang ameliorates tumor growth in cancer comorbid depressive symptoms via modulating gut microbiota-mediated TLR4", MyD88, Phytomedicine, pp.2021, 88[DOI]
- S. J. Lee, "The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis : A randomized double-blind controlled clinical trial", Clinical Nutrition, 33(6), pp.973~981 (2014)[DOI]
- "The effect of coapplication of Bangpungtongsung-san and probiotics on weight, blood lipid metabolism, intestinal permeability and intestinal microorganism in obese Korean women: Randomized Double Blinded Controlled clincal Trial"[URL]
- "Assessment of drug response in each Sasang typology by evaluating intestinal microbiota and intestinal permeability in obese patients: A Randomized, Double-blind Clinical Trial"[URL]
- "The effect of red ginseng on the metabolic syndrome by adjustmenting gut microbiota: a randomized, double-blind, placebo-controlled clinical trial"[URL]
- "The Efficacy and safety of Hwangryunhaedok-tang on Hangover and study of changes in gut microbiota composition"[URL]
- "An Observational Study on Effect of Herbal Medicine Treatment and Change of Gut Microbiome in Functional Dyspepsia Patients"[URL]
- "An exploratory study of 3 different complex herbal medicines for Sasang constitution types through microbiota and metabolomic approach : A Randomized, Double-blind Clinical Trial"[URL]
- National Institute for Korean Medicine Development, "Clinical practice guideline of Korean Medicine Sasang(Four)Constitutional Medicine Patterns" (2022), Kyungsan : National Institute for Korean Medicine Development
- J. Gong, "The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies", Clinical and Translational Medicine, 8(1), pp.1186~ (2019)[DOI]
- F. R. Ponziani, "Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma", Hepatology Communications, 6(6), pp.1492~1501 (2022)[DOI]